Pros | - | Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 4 Years | 12 Years | ||
Fund Size | 233 Cr | 8459 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 0.89% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 44 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.96%) Divi's Laboratories Ltd (8.97%) Apollo Hospitals Enterprise Ltd (6.35%) Max Healthcare Institute Ltd Ordinary Shares (5.71%) Torrent Pharmaceuticals Ltd (4.59%) | Sun Pharmaceuticals Industries Ltd (12.67%) Divi's Laboratories Ltd (8.07%) Lupin Ltd (7.26%) Cipla Ltd (6.29%) Apollo Hospitals Enterprise Ltd (5.97%) | ||
No of Sectors | 4 | 1 | ||
Top 3 Sectors | Health (94.75%) Basic Materials (2.92%) Financial Services (1.27%) | Health (100%) | ||
Equity % | 98.3% | 99.66% | ||
Debt % | - | - | ||
P/E | - | - | ||
P/B | - | - | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -2.98% | -0.47% | ||
3-Month Return | -2.98% | -0.78% | ||
6-Month Return | -1.58% | 0.04% | ||
1-Year Return | -6.66% | -0.1% | ||
3-Year Return | 20.78% | 22.18% | ||
5-Year Return | - | 16.74% |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Rohan Korde,Dhimant Shah | Sailesh Raj Bhan,Lokesh Maru,Divya Sharma,Kinjal Desai |